Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. www.bostonscientific.com › synergy-megatronSYNERGY MEGATRON™ - Boston Scientific

    The SYNERGY MEGATRON Stent System is purpose built for large proximal vessels so you can maximize performance where it is needed most. Receive Updates. Directions for Use. Indications, Safety, and Warnings. Modern PCI Treat Portfolio. Explore. Best-in-Class Axial & Radial Strength. Unmatched Overexpansion Range. Maximum Visibility.

    • Optimal Healing

      Optimal Healing. Unlike permanent polymer DES technology,...

    • Mega Strength

      3 Connectors Throughout the Body. For exceptional axial...

  2. www.bostonscientific.com › megatronSYNERGY MEGATRON™ Stent System - Boston Scientific

    SYNERGY MEGATRON is purpose built for large proximal vessels, including left main, bifurcations and ostial lesions. Available in 3.5 mm–5.0 mm diameters to maximize performance where it is needed most. Strength Overexpansion Visibility Lesion Scaffolding. Join our COMPLEX PCI COMMUNITY.

  3. www.bostonscientific.com › en-US › productsSYNERGY MEGATRON™ Indications, Safety and Warnings

    The SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at high risk for bleeding, with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation MI or documented silent ischemia due to atherosclerotic ...

  4. www.bostonscientific.com › en-EU › productsSYNERGY MEGATRON™ Stent System - Boston Scientific

    Information for use only in countries with applicable health authority registrations. SYNERGY MEGATRON™ provides a versatile stent model that can expand from 3.5 mm to 6.0 mm for tapered vessels, bifurcations and proximal optimization technique (POT).

  5. www.dicardiology.com › content › fda-clears-bostonFDA Clears Boston Scientific Synergy Megatron Drug ... - DAIC

    26 de ene. de 2021 · January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug-Eluting Stent (DES) system. The company said it is the first platform that is purpose-built for large, proximal vessels.